DETERMINATION OF THE MAIN METABOLITE (DESETHYL KBT-3022) OF A NEW ANTIPLATELET AGENT, KBT-3022 IN PLASMA BY GAS-CHROMATOGRAPHY

被引:0
|
作者
NAKADA, Y
SHIMADA, H
AWATA, N
机构
[1] Pharmaceuticals Research Center, Kanebo, Ltd., Miyakojima-ku, Osaka 534
关键词
ANTIPLATELET AGENT; ETHYL 2-[4,5-BIS(4-METHOXYPHENYL)THIAZOL-2-YL]PYRROL-1-YLACETATE; 2-[4,5-BIS(4-METHOXYPHENYL)THIAZOL-2-YL]PYRROL-1-YLACETIC ACID; METABOLITE; DETERMINATION; GC; PLASMA;
D O I
10.1248/yakushi1947.112.6_414
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A highly sensitive, accurate and reproducible gas chromatographic method for the determination of a main metabolite, 2-[4,5-bis(4-methoxy-phenyl)thiazol-2-yl] pyrrol-ylacetic acid (desethyl KBT-3022) of a new antiplatelet agent, ethyl 2-[4,5-bis(4-methoxyphenyl)thiazol-2-yl]pyrrol-1-ylacetate (KBT-3022), in the human or dog plasma has been developed. Desethyl KBT-3022 in the plasma was extracted with a mixture of n-hexane and dichloromethane (1 : 1), and was derivatized using pentafluorobenzyl bromide. The obtained pentafluorobenzyl derivative of desethyl KBT-3022 in the plasma was separated by high-performance liquid chromatography. After the separation, the pentafluorobenzyl derivative of desethyl KBT-3022 was detected by gas chromatography. Gas chromatography was performed with a Ultra 1 column (12 m x 0.22 mm i.d., film thickness 0.33-mu-m), using an electron capture detector. 2-[2-{4,5-Bis(4-methoxyphenyl)thiazol-2-yl}pyrrol-l-yl]propionic acid was used as an internal standard. The detection limit of desethyl KBT-3022 in the plasma was 0.2 ng/ml. The coefficients of variation were below 5.3%. This method was applied to the determination of the plasma concentration of desethyl KBT-3022 after oral administration of KBT-3022 to dogs.
引用
收藏
页码:414 / 417
页数:4
相关论文
共 50 条
  • [1] Antithrombotic effects in a rat model of aspirin-insensitive arterial thrombosis of desethyl KBT-3022, the main active metabolite of a new antiplatelet agent, KBT-3022
    Shimazawa, M
    Takiguchi, Y
    Umemura, K
    Kondo, K
    Nakashima, M
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 328 (2-3) : 183 - 189
  • [2] Antithrombotic effects, in a rat model of aspirin-insensitive arterial thrombosis, of desethyl KBT-3022, the main active metabolite of a new antiplatelet agent, KBT-3022
    Shimazawa, M
    Takiguchi, Y
    Umemura, K
    Kondo, K
    Nakashima, M
    THROMBOSIS AND HAEMOSTASIS, 1997, : P2824 - P2824
  • [3] The mechanism of action of KBT-3022, a new antiplatelet agent
    Matsuo, K
    Yokota, K
    Yamashita, A
    Oda, M
    GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM, 1997, 28 (02): : 229 - 235
  • [4] ANTIPLATETLET EFFECT AND MODE OF ACTION OF A NEW ANTIPLATETLET AGENT KBT-3022
    YAMASHITA, A
    MATSUO, K
    YOKOTA, K
    ITO, K
    NURIMOTO, S
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (02) : 340 - 340
  • [5] EFFECT OF KBT-3022, A NEW DIPHENYLTHIAZOLE DERIVATIVE, ON PLATELET FUNCTIONS
    YOKOTA, K
    YAMAMOTO, N
    MORIMOTO, Y
    YAMASHITA, A
    ODA, M
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1995, 47 (09) : 768 - 774
  • [6] ANTITHROMBOTIC EFFECT OF KBT-3022 ON EXPERIMENTAL THROMBOSIS MODELS
    YOKOTA, K
    YAMAMOTO, N
    YAMASHITA, A
    ITO, K
    NURIMOTO, S
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (05) : 1841 - 1841
  • [7] THE EFFECTS OF KBT-3022, A NEW ANTIPLATETLET AGENT, ON HEMORHEOLOGICAL PROPERTIES IN GUINEA-PIGS
    YAMAMOTO, N
    YOKOTA, K
    YAMASHITA, A
    ODA, M
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (01) : 118 - 121
  • [8] ANTITHROMBOTIC ACTIVITY OF KBT-3022 IN EXPERIMENTAL-MODELS OF THROMBOSIS
    YOKOTA, K
    YAMASHITA, A
    ODA, M
    JAPANESE JOURNAL OF PHARMACOLOGY, 1995, 68 (02): : 201 - 206
  • [9] Protective effect of KBT-3022, a new cyclooxygenase inhibitor, in cerebral hypoxia and ischemia
    Yamamoto, N
    Yokota, K
    Yoshidomi, M
    Yamashita, A
    Oda, M
    JAPANESE JOURNAL OF PHARMACOLOGY, 1995, 69 (04): : 421 - 428
  • [10] Antithrombotic effects of KBT-3022, a novel antiplatelet agent, in an arterial thrombosis model in the guinea-pig
    Shimazawa, M
    Takiguchi, Y
    Umemura, K
    Nakashima, M
    DRUG DEVELOPMENT RESEARCH, 1997, 40 (03) : 217 - 222